Is cerebrospinal fluid amyloid-β42 a promising biomarker of response to nusinersen in adult spinal muscular atrophy patients?

Alessandro IntronaGiammarco MilellaEustachio D'ErricoAngela FraddosioGaspare ScaglioneMaria UcciMaddalena Ruggieri Isabella Laura Simone

Published in: Muscle & nerve (2021)

The maintenance and promotion of wellness of residual motor neurons mediated by the restored level of SMN protein due to nusinersen could result in an increased level of amyloid peptides.

Keyphrases

cerebrospinal fluid
end stage renal disease
ejection fraction
newly diagnosed
spinal cord
prognostic factors
peritoneal dialysis
amino acid
spinal cord injury
young adults
childhood cancer